Advertisement
Feature Article

Hypertrophic cardiomyopathy. Keys to minimising morbidity and mortality

Avalon Moonen, Christopher Semsarian

Figures

© BSIP/MEDICAL IMAGES
© BSIP/MEDICAL IMAGES

Abstract

Hypertrophic cardiomyopathy can be an asymptomatic condition or can cause incapacitating symptoms. It is the most common cardiovascular genetic condition and genetic testing of affected individuals and their family members can help prevent the morbidity and mortality associated with hypertrophic cardiomyopathy.

 

Key Points

  • Hypertrophic cardiomyopathy (HCM) is a primary cardiomyopathy with an abnormally thickened myocardium.
  • Patients with HCM display clinical diversity, from no symptoms to heart failure and sudden cardiac death.
  • HCM is caused by mutations in genes that encode the sarcomere, the basic contractile unit of the heart.
  • Treatment options include lifestyle modififi cations, medical therapies and interventions such as implantable cardioverter defifi brillator therapy and surgical myectomy.
  • It is important to clinically screen fifi rst-degree relatives of patients with HCM.
  • HCM is best managed in the setting of a specialised multidisciplinary clinic.

Figures

© BSIP/MEDICAL IMAGES
© BSIP/MEDICAL IMAGES